Aurinia Pharmaceuticals
Logotype for Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals (AUPH) investor relations material

Aurinia Pharmaceuticals Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Aurinia Pharmaceuticals Inc
Q4 2025 earnings summary26 Feb, 2026

Executive summary

  • LUPKYNIS sales grew 25% year-over-year in 2025, reaching $271.3 million, with strong commercial momentum and robust patient growth.

  • Total revenue for 2025 was $283.1 million, up 20% from 2024, primarily driven by LUPKYNIS sales.

  • Net income for 2025 surged to $287.2 million, up 4,852% year-over-year, mainly due to a significant income tax benefit from the release of a valuation allowance on deferred tax assets.

  • Advanced aritinercept clinical development, initiating studies in autoimmune diseases and planning further trials in 2026.

  • Terminated VOCAL pediatric studies due to recruitment challenges, with plans to discuss pediatric commitments with the FDA.

Financial highlights

  • Q4 2025 total revenue was $77.1 million, up 29% year-over-year; net product sales of LUPKYNIS were $74.2 million, up 29%.

  • Full-year 2025 net product sales were $271.3 million, up 25% year-over-year.

  • License, collaboration, and royalty revenue for 2025 was $11.7 million, down 38% due to a prior year milestone payment.

  • Q4 2025 net income was $210.8 million, up 14,957% year-over-year, driven by a $175.1 million income tax benefit.

  • Full-year 2025 net income before taxes was $114.2 million, up 1,443% year-over-year.

Outlook and guidance

  • 2026 total revenue guidance is $315 million–$325 million, up 11%–15% from 2025.

  • 2026 net product sales guidance for LUPKYNIS is $305 million–$315 million, up 12%–16% year-over-year.

  • Guidance incorporates new competition, guideline implementation, and historical growth trends.

  • Focus remains on increasing LUPKYNIS adoption and advancing aritinercept clinical programs.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Aurinia Pharmaceuticals earnings date

Logotype for Aurinia Pharmaceuticals Inc
Q1 202611 May, 2026
Aurinia Pharmaceuticals
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Aurinia Pharmaceuticals earnings date

Logotype for Aurinia Pharmaceuticals Inc
Q1 202611 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Aurinia is a biopharmaceutical company driven by a relentless commitment to bring life-changing therapies, like voclosporin, to patients suffering from diseases with high unmet medical need. The Company’s lead product, voclosporin, is being investigated as a therapy for LN. The Company is initially targeting LN and has plans to study additional disease indications. The company is headquartered in Victoria, Canada.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage